Skip to main
MTSR
MTSR logo

Metsera Inc (MTSR) Stock Forecast & Price Target

Metsera Inc (MTSR) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Metsera Inc. is positioned favorably due to its development of highly selective biased agonists that do not activate β-arrestin, allowing for improved safety and tolerability through the potential use of lower doses. The company's ongoing clinical trials for its dual-agonist peptide profile indicate promising early results, with a 14% placebo-adjusted weight loss (WL) observed in the MET-097i study, reinforcing confidence in achieving a target of at least 13% WL in the upcoming VESPER-1 trial. Additionally, Metsera's advanced proprietary technologies and methods enhance the scalability and versatility of its NuSH analog peptide portfolio, contributing to a comprehensive strategy aimed at addressing key limitations seen in existing obesity therapies.

Bears say

Metsera Inc faces challenges with its lead compounds, TZP and MET-097i, which exhibit approximately one logarithmic reduction in potency compared to native GLP-1, potentially undermining their competitive edge against existing and emerging therapies. Additionally, the company’s reliance on comparators like Roche's CT-388, which displayed limited efficacy with significant tolerability issues, raises concerns about the relevance of their data and the feasibility of their product development strategy. Furthermore, the broader landscape for small to mid-cap biotechnology companies poses consistent risks, adding to Metsera's uncertain outlook as it attempts to scale its proprietary technologies and product portfolio.

Metsera Inc (MTSR) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metsera Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metsera Inc (MTSR) Forecast

Analysts have given Metsera Inc (MTSR) a Buy based on their latest research and market trends.

According to 4 analysts, Metsera Inc (MTSR) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metsera Inc (MTSR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.